HOME >> MEDICINE >> NEWS
Aventis Pasteur statement on HVTN 501 decision

Aventis Pasteur remains committed to the continued development of its ALVAC vector as a preventive AIDS vaccine. The knowledge gleaned from HIV Vaccine Trials Network (HVTN) 203 will be useful in moving future studies forward both in the U.S. and internationally.

There is no known correlate of protection for HIV vaccines. HVTN 501 was designed to determine possible correlates in addition to looking at efficacy of a prime-boost combination, using an ALVAC-HIV (vCP1452) prime and a gp120 boost. Because a correlate of protection analysis would not be able to be obtained from HVTN 501, that trial will not proceed. The decision, made by the NIAID and HVTN, was based on a review of data from HVTN 203 and is supported by the company.

However, the opportunity to see if the prime-boost, using ALVAC-HIV and gp120, is efficacious remains imminent. A phase III trial to be undertaken in Thailand with the Thai government and Walter Reed Army Institute of Research is planned to begin later this year. The Thai trial and HVTN 501 had different objectives. The Thai study is a straightforward community-based trial with efficacy as its outcome. The company will cooperate fully with the trial.

The NIAID and HVTN remain fully committed to several other trials using ALVAC-HIV (vCP1452) and the company intends to support them. HVTN (HIVNET) 026 looks at the safety and immunogenicity of ALVAC-HIV (vCP1452) and gp120 MN in populations outside of the U.S. HVTN 039 is studying whether a higher dose level of ALVAC-HIV (vCP1452) results in an enhanced HIV-specific immune response in vaccinees. HVTN 042 will seek to determine if there is a benefit to using a different boost, in this case lipopeptides and is in collaboration with the Agence Nationale de Recherche Sur de Sida (ANRS).

Importantly, all of these trials will help guide the companys R and D efforts in this area as well as build a continuing record of safety for these approaches. AL
'"/>

Contact: Robert Sebbag/Beth Waters
33-60-817-2183
Cooney Waters Group, Inc.
25-Feb-2002


Page: 1 2

Related medicine news :

1. Aventis Pasteur ready to meet nations needs for tetanus and diphtheria vaccine
2. Aventis Pasteur donates approximately 75 to 90 million doses of smallpox vaccine to the U.S.
3. Millennium, Aventis Pharma form novel alliance
4. Aventis Pharmaceuticals Allegra (Fexofenadine Hcl) 30-Mg tablets now available to treat seasonal allergies, chronic hives in children 6 to 11 years
5. NHLBI statement on oral contraceptive study
6. NIH panel issues State-of-the-Science statement on end-of-life care
7. Doctors statement in Mayo Clinic Proceedings reveals dark side of low-carb diets
8. American Heart Association consensus statement
9. NIA statement on IOM testosterone report
10. American Psychiatric Association issues statement on compulsive shopping
11. New statement proposes ways to stop deadly drug errors among heart, stroke patients

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/20/2017)... ... January 20, 2017 , ... ATP Science, an ... lives, recently attended the January ECRM Trade Show in Hilton Head, SC, benefiting ... its large range of supplements that keep the body functioning at its peak ...
(Date:1/20/2017)... ... January 20, 2017 , ... "TransFlare 4K Mystique comes with 44 colorful mysterious ... X," said Christina Austin - CEO of Pixel Film Studios. , TransFlare 4K ... 4K Mystique lens flare and light leak transitions have a very high-dynamic range for ...
(Date:1/20/2017)... ... ... “The Angel”: a heartwarming and earnest tale of faith and believing ... “The Angel” is the creation of published author, Marjorie Lund-Fontaine, a former professional violinist, ... , When asked of her new book, Marjorie says, “‘The Angel’ was written as ...
(Date:1/20/2017)... ... January 20, 2017 , ... D R Burton ... (OPEP) device, was featured in a study indicating superior performance against competitive products ... “Analysis of Three Oscillating Positive Expiratory Pressure Devices During Simulated Breathing“ was published ...
(Date:1/20/2017)... ... 2017 , ... “Knowledge is God’s Lighthouse”: a moving and colorful collection ... is the creation of published author, Gene Gaapf, a retired truck driver, and a ... have been writing since high school and have many different titles,” Gaapf mentions about ...
Breaking Medicine News(10 mins):
(Date:1/21/2017)... ResMed (NYSE: RMD ), BMC ( ... Florida ) today announced they have agreed on a global ... be permitted to sell their existing products in exchange for royalty ... to 3B to close the Florida litigation ... of liability or wrongdoing by any party. The ...
(Date:1/21/2017)... -- Research and Markets has announced the addition of ... Route Of Administration, End User - Forecast to 2025" report ... ... a CAGR of around 7.8% over the next decade to reach ... analyzes the global markets for Advanced Drug Delivery across all the ...
(Date:1/20/2017)... , Jan. 20, 2017  Ethicon ... acquired Megadyne Medical Products, Inc., a privately ... and markets electrosurgical tools used in operating ... intelligence of Ethicon,s* advanced energy devices with ... a major step forward in Ethicon,s goal ...
Breaking Medicine Technology:
Cached News: